Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.

With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.

AI creatives with access to Google’s Veo 2 text-to-video tool say it’s another “leap forward” for video generation Veo 2 improves on image quality, realistic motion and physics and adhering closely to even complex text prompts Still,

The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases and discrimination.

Nobel Prize winner Demis Hassabis thinks human trials will happen soon Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday.

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

As it looks to accelerate the pace of its AI development, Google is streamlining the teams building its AI services, platforms, and tools.

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have

The company fulfilled requests from Israel’s military for more access to AI tools as it sought to compete with Amazon, documents obtained by The Post show.

The Chinese startup DeepSeek has released a new AI reasoning model that appears to rival the abilities of a frontier model from OpenAI, the maker of ChatGPT.

Business Insider's diary takes you behind the scenes on day three of the World Economic Forum in Davos.